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signed patients into one of two mutually exclusive classes,
and (3) offered a benchmark for a comprehensive disease
management strategy for more involved diabetic patients.
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A MANAGED CARE COST ANALYSIS OF THE
TREATMENT OF PSORIASIS
Patterson HK, Gillis SM
SmithKline Beecham Phanmaceuticals, Collegeville, PA, USA
There is little published on the relative costs of treatments
in psoriasis.
OBJECTIVE: This study was designed to assess patterns
of medication use, costs, and health care resource utiliza-
tion among US managed care psoriasis patients.
METHODS: Members of 4 HMOs were identified using
pharmacy outpatient and hospital claims data for a
1-year period. Patients were selected if they had (l) at
least 2 claims for psoriasis (lCD-9 code 696, 696.1, and!
or 696.8) or (2) 1 claim for psoriasis and 1 claim for a
psoriasis drug or phototherapy. Descriptive data were
collected to determine psoriasis drug and therapy use,
and total and psoriasis-specific costs.
RESULTS: There were 2,868 members with psoriasis
identified. The data showed that 47.4% of the patients
were on monotherapy and 45% of the patients were on
poly therapy, defined as two or more of the psoriasis-spe-
cific drugs or therapies. This coincides with recent market
evaluations of psoriasis therapies. Topical corticosteroids
were used by 82 % of the patients. Claims for photo-
chemotherapy were made by 9% of members. Eighty per-
cent of patients received therapy from a dermatologist.
There were psoriasis-related hospitalizations for 11 % of
the patients. The median costs for psoriasis-related hospi-
talizations/patient were $252-$1,383 (range: $40-$18,933).
Median total psoriasis-related costs/patient were $155-$170
(range: $0-$24,334).
CONCLUSION: High potency topical corticosteroids re-
main the most commonly used medications for psoriasis.
Even though few patients were hospitalized for psoriasis,
the high costs of hospitalization made it one of the cost
drivers of this condition. Phototherapy procedures, office
visits for non-psoriasis-specific diagnoses, and total drug
costs for psoriasis were additional cost drivers of psoria-
sis treatment.
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CONSEQUENCES OF HIGH HEMATOCRIT
MAINTENANCE AMONG HEMODIALYSIS
PATIENTS.
Shih Y, Kauf TL
University of North Carolina School of Phanmacy, Chapel Hill,
NC, USA
EPO was approved for the treatment of anemia in renal
dialysis patients in 1989. In 1991, Medicare changed the
way it reimbursed for EPO, and, in response, there was
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an increase in average EPO dosages from 2,793 units to
3,200 units in the six-month period following the policy
change. This change, while meant to improve apparently
low EPO dosing, may have had the unintended conse-
quence of maintaining some patients at unnecessarily
high hematocrit levels. These patients may experience
problems associated with relatively high hernatocrits.
Thus, while some patients may have received too little
EPO prior to the policy change, now they may be receiv-
ing too much. Another recent change in EPO reimburse-
ment policy indicates this may be the case. After July 1,
1997 Medicare will reimburse EPO based on a 90-day
rolling average hematocrit measurement. If the average is
above 36.5%, Medicare will not pay for the EPO. This
policy implicitly assumes that high hematocrit levels are
directly related to inappropriately high doses of EPO.
OBJECTIVE: The purpose of this study is to examine the
incidence of complications resulting from abnormally
high hematocrits, such as vascular shunt thrombosis,
among patients with End-Stage Renal Disease (ESRD).
METHODS: This study uses data from the United States
Renal Data System (USRDS) and logistic regression to
model the incidence of adverse events as a function of he-
matocrit level while controlling for confounding factors
such as age, gender, ethnicity, weight, comorbidities, facil-
ity characteristics, dialysis modality, and dialysis history.
RESULTS: Preliminary results suggest that the incidence
of VST has increased since 1991.
CONCLUSION: This study provides Medicare with in-
formation concerning the appropriateness of the 36.5%
cutoff and the projected impact of the change in reim-
bursement.
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COMPARISON OF PREVALENCE RATES OF LOW
BACK DISORDERS OBTAINED FROM TWO
LARGE NATIONAL CLAIMS DATABASES
Dedhiya SD, Zhao SZ, Arguelles LM
G. D. Searle & Co., Skokie, IL, USA
Large national claims databases are sources of vital infor-
mation concerning health care resource utilization. How-
ever, the comparability of data obtained from such data-
bases has not yet been ascertained.
OBJECTIVE: To compare prevalence rates of low back
disorders obtained from two large national inpatient
claims databases and to study variations in length of stay
and corresponding costs.
METHODS: Data were obtained from two independent
databases with inpatient claims information including
ICD-9 codes for specific diagnoses, demographics, length
of stay (LOS), and payments or charges made. One of the
databases is a 20% national inpatient sample of all com-
munity hospitals in the U.S. (HCUP). The other national
database consists of data gathered for privately insured
population (MarketScan). Claims for specific diagnoses
of low back disorders (ICD-9 codes: 720.0-724.9) for
1994 were obtained. Using age, gender, and diagnosis-
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adjusted rates (direct method), the overall low back dis-
order rates were compared. Also age, gender, and diagno-
sis-specific low back disorder rates were compared
between two databases.
RESULTS: The overall adjusted prevalence rates of low
back disorders were 1.49 and 1.88 per 100 admissions
for HCUP and MarketScan, respectively. Significant dif-
ference was observed in the age, gender-adjusted rates for
diagnosis of displacement of lumbar intervertebral disc
without myelopathy, with MarketScan showing a higher
rate as compared to HCUP (1.06 vs. 0.781100 admis-
sions). The adjusted average LOS and age, gender, and
diagnosis-specific LOS were higher for HCUP than Mar-
ketScan. The specific and adjusted payments (based on
MarketScan) were, however, higher than the charges re-
ported in HCUP.
CONCLUSIONS: The prevalence rate of low back disor-
ders is higher in the MarketScan database than in HCUP.
The differences in the length of stay and associated costs
might be attributable to other variables such as geograph-
ical variations.
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OUTCOMES AND COST-BENEFIT OF INHALED
CORTICOSTEROID THERAPY INTRODUCTION
IN MEDICAID·ENROLLED ASTHMATIC
CHILDREN
Balkrishnan R, Norwood GJ
University of North Carolina at Chapel Hill, Chapel Hill,
NC, USA
OBJECTIVE: The purpose of this study was to assess the
clinical and economic impact of the introduction of inhaled
corticosteroid therapy for asthma in a cohort of children 12
years and younger who were North Carolina Medicaid en-
rollees.
METHODS: The North Carolina Medicaid claims data-
base was used to retrieve clinical and economic variables
for the purpose of this study. The case group, which was
comprised of 84 children who started corticosteroid in-
haler therapy between March 1994 and March 1995,
was followed up for 1 year before and 1 year after the
start of the therapy. The control group was comprised of
72 children with similar severity of asthma who remained
on any other therapy other than corticosteroids for a con-
tinuous 2-year period. Paired t-tests were used to com-
pare differences, and multiple regression analysis was
used to adjust for potential confounders.
RESULTS: There was a 58% reduction in hospital visits,
and a 19% reduction in physician visits in the case group
after initiation of inhaled corticosteroids. In the control
group, an increase of 34% in the number of outpatient vis-
its occurred in the second year. All the decreases and in-
creases were statistically significant. Children with regular
patterns of inhaled corticosteroid refills were found to be
significantly lower costing for Medicaid. However, after
adjusting for potential confounders, no significant change
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in health care costs per asthmatic child occurred as a result
of the introduction of inhaled corticosteroid therapy.
CONCLUSION: Overall, the study found that introduc-
tion of inhaled corticosteroids in a cohort of asthmatic
children enrolled in Medicaid was beneficial to Medicaid
because it brought about dramatic decreases in health
care utilization without additionally increasing costs.
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BAMBUTEROL IS A MORE COST-EFFECTIVE
TREATMENT THAN SALMETEROL IN ASTHMA
PATIENTS WITH NOCTURNAL SYMPTOMS
Crompton GKI, Brusasco 'fl, Eivindson N, Jamieson AH4,
Olsson H5, Svensson K5, Stahl P
'Western General Hospital, Edinburgh, UK; -Ospedale S
Martino, Genova, Italy: 3Aust-Agder Sentralsykehus,Arendal,
Norway: "Astra Clinical Research Unit. Edinburgh, UK; SAstra
Draco AB, Lund, Sweden
OBJECTIVE: To compare the cost-effectiveness of oral
bambuterol (B) 20 mg once daily with that of salmeterol
(S) pMDI 50 mg twice daily for treatment of asthma pa-
tients with nocturnal symptoms.
METHODS: 126 patients, aged 18-70 years and using
inhaled corticosteroids at a constant daily dose and with
an FEVI 40-85% of predicted normal value, were in-
cluded in this double-blind, randomized, parallel-group
study (2 weeks of run-in and 6 weeks of treatment) in the
UK, Italy, and Norway. During run-in, they had to show
a nocturnal awakening or early awakening due to asthma
symptoms that required rescue medication at least once,
and a 15% fall in overnight PEF on 3 out of the last 7
days. Morning and evening PEF were measured and
tremor was scored. The effectiveness variables in the cost-
effectiveness analysis were symptom-free days and num-
ber of nights with no awakenings. Costs for both study
and rescue medication were calculated.
RESULTS: There were no statistically significant differ-
ences between Band S regarding morning and evening
PEF (change from baseline), tremor, and the effectiveness
variables. Mean number of symptom-free days were 20-
25%, and mean number of nights with no awakenings
were 69-77%. Costs (study + rescue medication) were
lower during bambuterol treatment in all three countries.
UK Italy Norway
Bamb Salm Bamb Salm Bamb Salm
0.71 1.35 0.67 0.92 0.74 1.19
CONCLUSION: Treatment with bambuterol is more
cost-effective than treatment with salmeterol in asthma
patients with nocturnal symptoms.
